February 22, 2023
MAPS recently announced positive results from its second Phase III trial with MDMA-assisted therapy in the treatment of PTSD, with
February 15, 2023
The UK is home to one of the largest gambling markets in the world, generating £14 billion in profit in
February 8, 2023
From 1 July, psychiatrists in Australia will be able to prescribe MDMA for PTSD and psilocybin for treatment-resistant depression. The
January 30, 2023
Tryp Therapeutics recently announced interim results from its Phase II trial with psilocybin in the treatment of binge eating disorder,
January 25, 2023
2023 is expected to be a pivotal year for psychedelic-assisted therapy, with multiple compounds entering the final stages of drug
January 18, 2023
Awakn Life Sciences announced that its Phase III clinical trial with ketamine-assisted therapy for the treatment of alcohol-use disorder would
January 10, 2023
On Friday, atai Life Sciences shared results from its Phase IIa trial with PCN-101, R-ketamine, for treatment-resistant depression. Disappointingly, the
January 4, 2023
The Psychedelics Newsletter is the sector’s best-read investment focused newsletter, with over 25,000 subscribers. Featuring in-depth market analysis and interviews
December 28, 2022
In the final quarter of 2022, Beckley Psytech shared updates on its drug development pipeline and reported the acquisition of
December 14, 2022
Despite a challenging economic climate in the latter half of 2022, the year was marked by major milestones in psychedelic
December 7, 2022
UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows
November 30, 2022
On Tuesday, 29 November, PSYCH released the fourth edition of The Psychedelics as Medicine Report. The report, expanded to include
